Should less invasive surfactant administration (LISA) become routine practice in US neonatal units?

Venkatakrishna Kakkilaya¹ and Kanekal Suresh Gautham²

© The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc 2022

INTRODUCTION

The harmful effects of mechanical ventilation (MV) on the preterm lung are well established. Avoiding MV at birth and stabilization on continuous positive airway pressure (CPAP) decreases the composite outcome of death or bronchopulmonary dysplasia. Although preterm infants are increasingly being admitted to the neonatal intensive care unit on CPAP, centers differ in the ability to manage infants primarily on CPAP. Over the last decade, less invasive surfactant administration (LISA), a method of administering surfactant with a thin catheter, has been devised and has been shown to decrease the need for MV and improve outcomes compared to surfactant administration via an endotracheal tube following intubation. While LISA has been widely adopted in Europe and other countries, its use is not widespread in the United States. This article provides a summary of the existing evidence on LISA, and practical guidance for US units choosing to implement a change of practice incorporating optimization of CPAP and LISA.

REVIEW ARTICLE

This article will help neonatal units in the US develop guidelines for LISA, provide optimal respiratory support for infants with respiratory distress syndrome, improve short- and long-term outcomes of preterm infants, and potentially decrease costs of NICU care.

IMPACT:

- The accumulated body of evidence for less invasive surfactant administration (LISA), a widespread practice in other countries, justifies its use as an alternative to intubation and surfactant administration in US neonatal units.
- This article summarizes the current evidence for LISA, identifies gaps in knowledge, and offers practical tips for the implementation of LISA as part of a comprehensive non-invasive respiratory support strategy.
- This article will help neonatal units in the US develop guidelines for LISA, provide optimal respiratory support for infants with respiratory distress syndrome, improve short- and long-term outcomes of preterm infants, and potentially decrease costs of NICU care.

THE LISA PROCEDURE

The first report of surfactant administration using a feeding tube in preterm infants with RDS maintained on CPAP was by Verder et al. ²⁸ Subsequently, three LISA techniques have been described in randomized controlled trials. ²⁸–³¹ Common to all three is the administration of surfactant through a thin catheter too small to be used for PPV. The thin catheter is inserted into the trachea under visualization with a laryngoscope blade, while the infant is maintained on CPAP. Surfactant instilled into this catheter moves down the airways with the infant’s own respiratory effort. In the

¹Division of Neonatal-Perinatal Medicine, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA. ²Division of Neonatology, Department of Pediatrics, Nemours Children’s Health, Orlando, FL, USA. ³email: Venkat.Kakkilaya@UTSouthwestern.edu

Published online: 19 August 2022
Cologne method, first described by Kribs et al., the thin catheter was a 4 French feeding tube inserted 1.5 cm below the vocal cords under direct laryngoscopy with the aid of Magill forceps. Atropine 0.025 mg/kg1 was given prior to the procedure.32 In the Take Care method, described by Kanmaz et al., the thin catheter was a shortened 5 Fr feeding tube, inserted without using Magill forceps or premedication to a depth of 1 cm in infants 25–26 weeks, 1.5 cm in infants 27–28 weeks, and 2 cm in infants 29–32 weeks GA.30 In the MIST method (also known as the Hobart method) Dargaville et al. administered surfactant without premedication through a 16 gauge vascular catheter (Angiocath, BD, Sandy, Utah) inserted to the same depth as in the Take Care method.31

There are no prospective clinical trials comparing the safety and effectiveness of flexible versus stiff catheters. However, an in-vitro study comparing different catheters in a mannequin model showed that stiff catheter insertion is quicker and easier compared to flexible catheters.34 A single-center retrospective study reported no difference between these two types of catheters in the rate of procedural success.35 The stiffer and straight catheter is an attractive option for centers where oral intubation is the preferred practice and use of Magill forceps is uncommon.

The success rate reported in randomized control trials (RCT) for insertion of the catheter on the first attempt is between 72 and 95%.28,29,31 The adverse events associated with thin catheter insertion include coughing, gagging, desaturation, bradycardia, and surfactant reflux (Table 1). The reported frequency of desaturation episodes with LISA ranges from 12 to 100% and the frequency of bradycardia ranges from 6 to 32%. Similarly, the need for rescue PPV for these events ranged between 6 and 14%. However, the definition of events and criteria for intervention varied across the studies. In the OPTIMIST-A trial that used stiff catheters, the frequency of LISA-related events requiring PPV (14%) or emergent intubation (0.4%) was relatively uncommon.31

Two custom-made stiff catheters specifically designed for LISA (with centimeter markings for determining insertion depth) are currently not available in the US—a straight catheter similar to the

| Table 1. Adverse events during LISA vs ETT surfactant. |

| Study and technique | Success rate and adverse events LISA vs ETT surfactant (%), p value |
|---------------------|---------------------------------------------------------------|
| Göpel et al.29       | First attempt success rate: 95% in the LISA group            |
| 4 French feeding tube, Cologne methoda | Adverse events during ETT intubation not reported |
| Optional sedative, analgesic, and atropine | Bradycardia (HR <100): 6% in the LISA group |
| Kribs, 201530        | First attempt success rate between LISA and ETT surfactant (73% in both) |
| 5 French feeding tube, Cologne method | ↑ Bradycardia (HR <100) in the LISA group (11 vs 3%, p = 0.029)d |
| No sedative or analgesic | ↑ Desaturation (SpO2 <80) in the LISA group (56 vs 26%, p  <0.001) |
| Kanmaz et al., 201330| First attempt success rate between groups (82 vs 90%, p = 0.07) |
| 5 French feeding tube shortened to 33 cm at hub | ↑ Coughing, gagging in the LISA group (11 vs 0%) |
| Take Care methodb   | ↑ Surfactant reflux in the LISA group (21 vs 10%, p = 0.02) |
| No premedication    | ↓ Need for face mask PPV in the LISA group (12 vs 100%) |
| Mohamadizadeh, 201549| ↑ First attempt in the LISA group (88 vs 72%, p = 0.08) |
| 4 French feeding tube, Cologne method | ↓ Adverse events with LISA (11 vs 31%, p = 0.049) |
| Premedication with atropine 25 mcg/kg to LISA group | ↔ First attempt success rate between groups (89 vs 86%) |
| Bao, 2015, MIST, LISA vs rescue50 | ↔ First attempt success rate between two groups (94 vs 98%) |
| Hobart methodc      | ↔ First attempt success rate between two groups (94 vs 98%) |
| Choupani et al., 201854| First attempt success rate (96 vs 90%) |
| Hobart method       | ↓ Desaturation (SpO2 <80) in the LISA group (12 vs 29%, p = 0.028) |
| No premedication    | ↔ Cough (0 vs 4%) |
| Yang et al., 201955  | ↑ First attempt success rate between two groups (94 vs 98%) |
| 6 French feeding tube, Cologne method | ↔ Surfactant reflux (13 vs 6%) |
| Olivier et al., 201752 | ↓ Need for laryngoscopy attempts (2.3 ± 1.9 vs 2.3 ± 1.2) |
| 5 French feeding tube, Cologne method | ↑ Surfactant reflux in the LISA group (66%) |
| Premedication with atropine 20 mcg/kg and fentanyl 1 mcg/kg | ↑ Moderate desaturation (SpO2 60–80) in the LISA group (58 vs 16%, p ≤ 0.01) |
| Dargaville, 202131  | Adverse events with ETT intubation not reported |
| Hobart method       | First attempt success rate 76% with LISA |
| Atropine, sucrose optional | Hypoxemia (SpO2 <80 for 30 s) 42% with LISA |
| No sedatives or opioids | Bradycardia (HR <100 for >10 s) 32% with LISA |

GA gestational age, SpO2: oxygen saturation, HR heart rate, PPV positive pressure ventilation.
aCologne method: insertion of a flexible catheter (i.e., feeding tube) below the vocal cords with direct laryngoscopy using Magill forceps.
bTake Care method: insertion of a flexible catheter (i.e., feeding tube) below the vocal cords with direct laryngoscopy using Magill forceps.
cHobart method: insertion of a stiff catheter (i.e., 16 G 5.25” vascular catheter) below the vocal cords with direct laryngoscopy.
dFirst % value refers to LISA group and second value refers to control group. 
↑ higher, ↓ lower, ↔ Not significantly different.
Hobart catheter (LISA Cath, Chiesi Farmaceutici S.p.A, Parma, Italy), and a straight catheter with an angulated tip (Surfacath, Vygon, Swindon, UK). A multicenter RCT to evaluate the LISA Cath,\(^3\)\(^6\) is no longer recruiting patients due to manufacturing issues related to the catheter. Another plastic application device with a soft tip, with an angle similar to Magill forceps (NeoFact, Lyomark Pharma, Germany) has been evaluated in a feasibility trial.\(^3\)\(^7\),\(^3\)\(^8\)

A large body of evidence (summarized below) has accumulated demonstrating the benefits of LISA. However, several questions still remain. LISA requires direct laryngoscopy or video laryngoscopy, which are associated with adverse events such as increased intracranial pressure,\(^9\),\(^14\), higher systemic blood pressure,\(^9\) prolonged hypoxemia,\(^9\) bradycardia,\(^4\) and pain.\(^4\) CPAP transmission might decrease during direct laryngoscopy. The LISA catheter may occupy over 50% of airway diameter of extremely low GA neonates, potentially causing hypoxia and poor ventilation.\(^4\),\(^5\) There are no reliable methods of confirming the placement of thin catheter into the airway, and therefore there is a risk of inadvertent esophageal administration of surfactant if the catheter is misplaced. With respect to the type of laryngoscopy for LISA, thus far no studies have evaluated the use of video laryngoscopy during LISA. Finally, there are concerns about respiratory depression with the use of medications for analgesia and sedation with LISA.\(^6\) This poses challenges in balancing the pain and discomfort from laryngoscopy against the harmful effects of intubation and MV that might result from use of sedation.\(^7\)

**THE EVIDENCE FOR LISA**

Thus far LISA has been evaluated in 20 trials in preterm infants,\(^2\)\(^6\)\(^3\),\(^1\)\(^4\)\(^3\) of which 17 are summarized in this review. Three are excluded—one that evaluated CPAP and NIPPV, and two that evaluated the role of sedation during LISA.\(^5\),\(^6\) Of the 17 trials, only 2 were powered for the primary outcome of death or BPD,\(^2\)\(^8\),\(^3\)\(^1\) and only 2 trials included infants born <25 weeks GA.\(^2\)\(^8\),\(^3\)\(^0\) Details of these trials are provided in Tables 2 and 3, with key findings summarized below.

### Table 2. Randomized controlled trials evaluating LISA vs surfactant via endotracheal tube and continued mechanical ventilation.

| Author/year/design | LISA group threshold/method | Control group threshold/method | Results LISA vs ETT surfactant (% or p value, ARD (95% CI)) |
|---------------------|-----------------------------|--------------------------------|-----------------------------------------------------|
| Kribbs et al., 2015\(^2\)\(^8\) | FiO\(_2\) > 0.3, CPAP 5–8 Silverman score ≥ 5 4 Fr feeding tube, Cologne method\(^a\) | FiO\(_2\) > 0.3, CPAP ≥ 8 cm H\(_2\)O | n = 211  
Survival without BPD\(^*\) (67 vs 59%, p = 0.02), 8.6 (5–22)  
† Survival without major complications (51 vs 36%, p = 0.02), 15 (1.4 to 28)  
¶ MV during NICU stay, (75 vs 99%, p = 0.001), 24 (16 to 34)  
| Dargaville et al., 2021\(^3\)\(^1\) | FiO\(_2\) ≥ 0.3, CPAP ≥ 8 cm H\(_2\)O | FiO\(_2\) ≥ 0.3, CPAP ≥ 8 cm H\(_2\)O or NIV Sham procedure: only gentle repositioning Intubation criteria: FiO\(_2\) ≥ 0.45, persistent apnea Decision to give surfactant after intubation was per physician discretion | n = 485  
↔ Death or BPD, (44 vs 50%, p = 0.10), –6.3 (–14.2 to 1.6)  
↔ Mortality (12 vs 8%, p = 0.30), 2.1 (–3.6 to –7.6)  
¶ BPD (37 vs 45%, p = 0.03), –7.8 (–15 to –0.7)  
| Gopel et al., 2011\(^2\)\(^9\) | FiO\(_2\) > 0.3, CPAP ≥ 8 cm H\(_2\)O 4 Fr Feeding tube, Cologne method | Physician-dependent threshold for intubation. Surfactant per physician discretion Surfactant via ETT | n = 220  
↔ Need for MV (or if not intubated PaCO\(_2\) > 65 or FiO\(_2\) > 60% for ≥2 h) between 25 and 72 h\(^+\) (28 vs 46%, p = 0.008), –0.18 (–0.30 to –0.05)  
¶ MV during NICU stay (33 vs 73%), –0.40 (–0.52 to –0.27)  
| Olivier et al., 2017\(^7\)\(^2\) | FiO\(_2\) ≥ 0.35 at CPAP 6 cm H\(_2\)O 5 Fr feeding tube, Cologne method | Physician-dependent threshold for intubation. Surfactant per physician discretion Surfactant via ETT | n = 45  
↔ MV/pneumothorax requiring chest tube within 72 h of life\(^*\) (33 vs 90%, p ≤ 0.001), 0.57 (95% CI 0.54 to 0.60)  
↔ Average laryngoscopy attempts (mean ± SD) 2.3 ± 1.2 vs 2.3 ± 1.9 |

**BWT** birth weight, **GA** gestational age, **MV** mechanical ventilation, **PDA** hemodynamically significant PDA, **OR** odds ratio, **ARD** absolute risk difference.

\(^a\)Cologne method: insertion of a flexible catheter (i.e., feeding tube) below the vocal cords with direct laryngoscopy using Magill forceps.

\(^b\)Hobart method: insertion of a stiff catheter (i.e., 16 G 5.25” vascular catheter) below the vocal cords with direct laryngoscopy.

\(^\dagger\) Primary outcome defined a priori.

\(^\ddagger\) First % value refers to LISA group and second value refers to control group.

\(^\ddagger\) Higher, \\(\ddagger\) lower, \(\ddagger\) Not significantly different.
Lower, \( \rightarrow \) Not significantly different.

\( \uparrow \) Higher, \( \downarrow \) Lower, \( \leftrightarrow \) Not significantly different.

\( \rightarrow \) BPD bronchopulmonary dysplasia, HOL hours of life, hsPDA hemodynamically significant patent ductus arteriosus, NEC necrotizing enterocolitis, NIPPV non-invasive positive pressure ventilation.

\( ^a \)Take Care method: insertion of a flexible catheter (i.e., feeding tube) below the vocal cords with direct laryngoscopy without using Magill forceps.

\( ^b \)Cologne method: insertion of a flexible catheter (i.e., feeding tube) below the vocal cords with direct laryngoscopy using Magill forceps.

\( ^c \)Hobart method: insertion of a stiff catheter (i.e., 5 Fr feeding tube with ophthalmic forceps) below the vocal cords with direct laryngoscopy.

\( ^d \)Primary outcome defined a priori.

\( ^e \)Primary outcome defined a posteriori.

### Table 3. Randomized controlled trials evaluating LISA vs INSURE.

| Study design | LISA vs INSURE threshold, method | Results |
|--------------|---------------------------------|---------|
| Kanmaz et al., 2012\(^3\) | \( \text{FiO}_2 \geq 0.4 \% \) within 2 HOL, CPAP 5–7 cm H\(_2\)O | \( n = 200 \)
| Single center | LISA—only by experienced neonatologists | \( \downarrow \) Need for MV within 72 HOL\( ^d \) in the LISA group |
| <32 weeks GA | 5 Fr Feeding tube, Take Care method\(^b\) | \( \downarrow \) Duration of MV and CPAP in the LISA group |
| Poractant alfa, 100 mg/kg | No premedication | \( \leftrightarrow \) BPD |
| Mirnia, 2013\(^4\,46\,49\) | \( \text{FiO}_2 > 0.3, \text{CPAP} 8–10 \text{ cm H}_2\text{O} \) | \( n = 136 \)
| 3 centers | 5 Fr feeding tube, Take Care method | \( \leftrightarrow \) Need for MV within 72 HOL in the LISA group |
| 27–32 weeks GA | Premedication with atropine 5 mcg/kg | \( \downarrow \) Mortality and NEC in the LISA group |
| Poractant alfa, 100 mg/kg | No premedication | \( \leftrightarrow \) Need for MV within 72 HOL\( ^d \) between groups |
| Mohammadiazadeh et al., 2015\(^5\,49\) | \( \text{FiO}_2 > 0.4, \text{CPAP} 6 \text{ cm H}_2\text{O} \) | \( n = 38 \)
| 2 centers | 4 Fr Feeding tube, Cologne method\(^b\) | \( \leftrightarrow \) Need for MV within 72 HOL\( ^d \) between groups |
| <34 weeks GA | Premedication with atropine 25 mcg/kg | \( \leftrightarrow \) BPD |
| 1000–1800 g | No premedication | \( \leftrightarrow \) Need for MV within 72 HOL\( ^d \) between groups |
| Poractant alfa, 200 mg/kg | No premedication | \( \leftrightarrow \) Need for MV within 72 HOL\( ^d \) between groups |
| Bao et al., 2015\(^5\,50\) | \( \text{FiO}_2 \geq 0.3 \) for 28–29 weeks GA, \( \geq 0.35 \) for 30–32 weeks GA, CPAP \( \geq 7 \text{ cm H}_2\text{O} \) | \( n = 100 \)
| Single center, pilot | Hobart method\(^c\) | \( \leftrightarrow \) Need for MV within 72 HOL between groups |
| 28–32 weeks GA | No premedication | \( \leftrightarrow \) Duration of MV between groups |
| Poractant alfa, 200 mg/kg | No premedication | \( \leftrightarrow \) Duration of MV between groups |
| Mosayebi et al., 2018\(^5\,53\) | \( \text{FiO}_2 > 0.4, \text{CPAP} 5–8 \text{ cm H}_2\text{O} \) | \( n = 53 \)
| Single center | 5 Fr feeding tube, Take Care method | \( \leftrightarrow \) Need for MV within 72 HOL\( ^d \) between groups |
| 28–34 weeks GA | No premedication | \( \leftrightarrow \) Need for MV within 72 HOL\( ^d \) between groups |
| No premedication | \( \leftrightarrow \) Need for MV within 72 HOL\( ^d \) between groups |
| Mohammadiazadeh et al., 2015\(^5\,54\) | \( \text{FiO}_2 > 0.4, \text{CPAP} 6 \text{ cm H}_2\text{O} \) | \( n = 104 \)
| Single center | Hobart method | \( \leftrightarrow \) Need for MV within 72 HOL\( ^d \) between groups |
| No GA or weight criteria, | No premedication | \( \leftrightarrow \) Need for MV within 72 HOL\( ^d \) between groups |
| Poractant alfa, 200 mg/kg | No premedication | \( \leftrightarrow \) Need for MV within 72 HOL\( ^d \) between groups |
| Halim, 2019\(^5\) | \( \text{FiO}_2 \geq 0.3, \text{CPAP} 5–7 \text{ cm H}_2\text{O} \) | \( n = 100 \)
| Single center | 6 Fr Feeding tube, Take Care method | \( \downarrow \) Need for MV in the LISA group |
| \( \leq 34 \text{ weeks GA} \) | No premedication or sedation | \( \downarrow \) Duration of MV in the LISA group |
| Beractant, 100 mg/kg | No premedication | \( \downarrow \) Duration of MV in the LISA group |
| Boskabadi et al., 2019\(^5\,57\) | \( \text{FiO}_2 > 0.4, \text{CPAP} 5–8 \text{ cm H}_2\text{O} \) | \( n = 40 \)
| Single center | 5 Fr feeding tube, Take Care method | \( \downarrow \) Duration of MV in the LISA group |
| <32 weeks GA | No premedication | \( \downarrow \) Duration of MV in the LISA group |
| No premedication | \( \downarrow \) Duration of MV in the LISA group |
| Choupani et al., 2018\(^5\,58\) | \( \text{FiO}_2 > 0.4, \text{CPAP} 6 \text{ cm H}_2\text{O} \) | \( n = 350 \)
| Single center | Hobart method or 6 Fr feeding tube without Magill forceps | \( \downarrow \) MV within 72 HOL\( ^d \) in the LISA group |
| No GA or weight criteria, | No premedication | \( \downarrow \) BPD in the LISA group |
| Poractant alfa, 200 mg/kg | No premedication | \( \downarrow \) NEC in the LISA group |
| Halim, 2019\(^5\) | \( \text{FiO}_2 \geq 0.3, \text{CPAP} 5–7 \text{ cm H}_2\text{O} \) | \( n = 350 \)
| 3 centers | 6 Fr Feeding tube, Take Care method | \( \downarrow \) NEC in the LISA group |
| \( \leq 34 \text{ weeks GA} \) | No premedication or sedation | \( \downarrow \) NEC in the LISA group |
| Bovine lung extract, 135 mg/kg | \( \downarrow \) NEC in the LISA group |
| Yang et al., 2020\(^5\) | \( \text{FiO}_2 > 0.4, \text{CPAP} 6 \text{ cm H}_2\text{O} \) | \( n = 97 \)
| Single center | 6 Fr feeding tube, Cologne method (insertion depth: 2 cm for 32–34 weeks, 2.5 cm for 34–35 weeks GA) | \( \leftrightarrow \) Procedural adverse events between two groups |
| 32–36 weeks GA | No premedication | \( \leftrightarrow \) Need for MV or pneumothorax between groups |
| No premedication | \( \leftrightarrow \) Need for MV or pneumothorax between groups |
| Han, 2020\(^6\) | \( \text{FiO}_2 > 0.4, \text{CPAP} 5–6 \text{ cm H}_2\text{O} \) | \( n = 298 \)
| 8 centers | 5 Fr feeding tube with ophthalmic forceps | \( \leftrightarrow \) BPD\( ^d \) between the groups |
| 25–31 weeks GA | No premedication | \( \leftrightarrow \) hsPDA in the LISA group |
| Calf pulmonary surfactant, 70–100 mg/kg | \( \leftrightarrow \) hsPDA in the LISA group |
| Gupta et al., 2020\(^5\,59\) | \( \text{FiO}_2 > 0.3, \text{NIPPV} \text{PEEP} 5–6 \text{ cm H}_2\text{O} \) | \( n = 58 \)
| Single center | 5 Fr feeding tube, Cologne method | \( \leftrightarrow \) MV within 72 HOL\( ^d \) between groups |
| 28–34 weeks GA | No premedication | \( \leftrightarrow \) MV within 72 HOL\( ^d \) between groups |
| Poractant alfa 200 mg/kg | No premedication | \( \leftrightarrow \) MV within 72 HOL\( ^d \) between groups |
| Pareek et al., 2021\(^5\,52\,63\) | \( \text{FiO}_2 > 0.3 \) | \( n = 40 \)
| Single center | 5 Fr Feeding tube, ± Magill forceps | \( \leftrightarrow \) Difference adverse events between two groups |
| 28–36 weeks GA | No premedication | \( \leftrightarrow \) Difference adverse events between two groups |
| NIPPV, Silverman Score \( \geq 4 \), \( \text{FiO}_2 > 0.3 \) | No premedication | \( \leftrightarrow \) Difference adverse events between two groups |
Comparison 1. LISA vs surfactant administration through an ETT at a similar FiO₂ threshold as the LISA arm and continued MV without attempting to extubate the infant soon after surfactant administration

The multicenter study by Kribs et al. is the only study in this category and the only one to evaluate LISA in 23–24 weeks GA infants. The primary outcome (death or BPD) was not different between the two groups. However, a higher proportion of infants in the LISA group survived without major morbidity (Table 2). Among infants in the LISA group, 53% escaped MV during the first 72 h of life (HOL). The need for MV during NICU stay was also lower with the LISA group - this effect was mainly seen in 25–26 weeks GA infants. Of infants 23–24 weeks GA, 93% required MV.

Comparison 2. LISA vs selective ETT intubation and continued MV based either on physician judgment or criteria established a priori, with surfactant administration based on physician judgment

In the first RCT evaluating LISA, infants were enrolled in 12 centers within the German Neonatal Network (GNN). The primary outcome (the need for MV or not being ventilated but having PaCO₂ >65 or FiO₂ >0.6 for >2 h between 25 and 72 HOL) was lower in the LISA group compared to control group. There were no differences between the two groups in important clinical outcomes. A large blinded multicenter trial (OPTIMIST-A trial), of 25–28 weeks GA infants involving 33 international centers had a planned enrollment of 606 infants. After 10 years, with 485 infants enrolled, it was terminated due to impaired enrollment, a consequence of the Covid-19 pandemic. Infants were randomized if they required FiO₂ 0.3 at CPAP 5–8 cm H₂O. The control group of infants underwent a sham procedure that included only repositioning but mimicked LISA procedure in team interaction and duration. Infants in both groups were intubated at threshold of FiO₂ 0.4–0.45, and received surfactant based on clinicians’ judgment. Overall, there were no differences in baseline demographics between the two groups. Infants in the 25–26 weeks GA stratum had a higher frequency of incomplete or absent antenatal steroid use, multiple births, and male sex. There was no difference between the groups in the composite primary outcome of the study—death or BPD (43.6% in LISA group vs 49.6 and in controls, RR 0.87, 95% CI 0.74–1.03). However, compared to the control group, infants in the LISA group had a lower incidence of BPD, and pneumothorax, and a decreased need for MV and PDA treatment. An exploratory subgroup analysis showed higher mortality in the LISA group for 25–26 weeks GA infants compared to control group infants (15.6 vs 6.90%, RR 1.95, 95% CI 0.9–4.23).

A third RCT, the only one to evaluate LISA in 32–36 weeks GA infants used premedication in both groups as part of the protocol. The primary outcome of the study—incidence of air leak or need for MV within 72 HOL—was lower in the LISA arm. A meta-analysis of these trials showed that compared to INSURE, LISA decreases death or BPD, need for MV within 72 h, and mortality.

Systematic reviews and meta-analyses of comparisons of LISA vs surfactant via ETT

Several systematic reviews with meta-analyses have addressed trials comparing LISA with ETT surfactant. A recent Cochrane systematic review included 16 RCTs comparing LISA with ETT surfactant. It does not include data from the OPTIMIST-A trial described above. Compared to TTT surfactant, LISA decreased death or BPD (RR 0.59, 95% CI 0.48–0.73), BPD (RR 0.57, 95% CI 0.45–0.74, number needed to treat for benefit [NNTB] 13, 95% CI 9–24) and the need for MV within 72 HOL (RR 0.63, 95% CI 0.54–0.74, NNTB 8, 95% CI 6–12). LISA also decreased mortality and severe intracranial hemorrhage (RR 0.63, 95% CI 0.42–0.96, NNTB 22, 95% CI 12–193), and in-hospital mortality (RR 0.63, 95% CI 0.47–0.84 NNTB 20, 95% CI 12–58). The authors of this review noted significant methodological weaknesses among included studies that decreased the certainty of evidence, with high risk of bias in eight studies related to randomization, blinding of outcome assessment, and incomplete or selective outcome reporting. However, a sensitivity analysis excluding these 8 studies showed results similar to those of the overall meta-analysis. Meta-analyses of a subgroup of studies comparing LISA with INSURE also showed a decrease in death or BPD, mortality, and need for MV within 72 HOL with LISA (Table 4).

Other methods of surfactant administration

Several alternative methods of surfactant administration without intubation have been or are being investigated, including pharyngeal instillation,74,75 nebulization (aerosolization)76,77 and laryngeal mask airway (LMA).78–80 None of these methods has been compared against LISA. Therefore, their potential superiority over LISA requires investigation. One ongoing trial is comparing LISA (MIST) versus surfactant administration through an LMA.

Long-term neurodevelopmental outcome of infants managed with LISA

Among infants enrolled in the Göpel et al. study, the neurodevelopmental outcome was assessed at 18–36 months in 86% of eligible infants. Compared to control infants, infants managed with LISA did not differ in the Bayley II mental development index (98.5 ± 16.6% vs 92 ± 24, p = 0.07) and psychomotor development index (89 ± 19 vs 88 ± 23, p = 0.75). Among infants enrolled in the Kribs et al. trial, the neurodevelopmental outcome at 2 years was assessed in 86% of survivors. Compared to the LISA group, a higher proportion of control infants had low (<70) Bayley II psychomotor development score (22 vs 42%, p = 0.012) and low mental developmental index (<70) in the 25–26 weeks GA stratum (4 vs 21%, p < 0.008). These two studies suggest that neurodevelopmental outcomes are not worse, and possibly better with LISA compared to surfactant administration by ETT and continued MV. Of note, there are no studies comparing neurodevelopmental outcomes of infants treated with LISA vs INSURE.

Premedication for LISA

The role of premedication with LISA is not well evaluated. Of the 17 trials described above, only one included fentanyl (1 mcg/kg) as part of the protocol (Tables 1–3). Two infants in the LISA arm of this study required intubation and MV due to chest wall rigidity. A recent unblinded RCT (n = 34) showed better pain scores in infants receiving fentanyl (1 mcg/kg) during LISA. Several observational studies from Europe have reported the use of sedatives such as propofol, ketamine, and midazolam with LISA.84–88 In one RCT of 78 infants, compared to infants receiving no sedation prior to LISA, those receiving propofol had lower pain scores but a higher incidence of hypoxia requiring PPV. A systematic review that included both observational studies and RCTs found no significant impact on the duration of procedure or...
procedure success rates from sedation but a higher risk of desaturation, apnea, and need for non-invasive PPV, albeit with a low certainty of evidence. Currently, there is insufficient evidence to make strong recommendations about the routine use of sedatives/opioids for LISA. Further studies are urgently needed to address this issue. Until we have more evidence, it is reasonable to consider an individualized approach based on an infant’s GA, respiratory drive, and bedside assessment of pain and distress to guide the use of opioids and sedatives. If a decision is made to administer medication for pain, slow infusion of low dose fentanyl (0.7 mcg/kg) as recommended by a consensus guideline from the Neonatal–Perinatal� Association of Canada. 

Although atropine is recommended as part of premedication for non-emergent endotracheal intubation, only three RCTs comparing LISA and ETT surfactant included atropine as part of the protocol. A prospective observational study of LISA procedure from two tertiary centers in Australia reported that the use of atropine decreased the incidence of bradycardia associated with LISA procedure. Further studies are necessary before routine use of atropine can be recommended for LISA.

**Optimum threshold and timing of LISA**

Early surfactant therapy (≤2 HOL) improves outcomes compared to delayed therapy in preterm infants mechanically ventilated at birth. In studies evaluating early CPAP selective surfactant therapy was generally administered after ET intubation at a threshold of 0.4–0.6 FiO2 and CPAP level 5–8 cm H2O. None of these studies reported an association between timing of surfactant administration and outcome. Interestingly, nearly 50% of infants ≤28 weeks GA infants in these studies did not require surfactant therapy and escaped MV. In one large RCT, infants in the CPAP arm who received CPAP 8 cm H2O at birth with a threshold FiO2 of 0.6 for surfactant therapy had a higher incidence of pneumothorax.

**Table 4. Meta-analyses of studies comparing LISA with surfactant administration via ETT.**

| Author | Results | Certainty of evidence according to GRADE |
|---|---|---|
| Abdel-Latif et al., 2021 | Compared to ETT surfactant, LISA lead to: ↓ Death or BPD (RR 0.59, 95% CI 0.48–0.73), NNB 9 (95% CI 7–16) ↓ BPD (RR 0.57, 95% CI 0.45–0.74), NNB 13 (95% CI 9–24) ↓ MV within 72 h (RR 0.63, 95% CI 0.54–0.74), NNB 8 (95% CI 6–12) ↓ Severe IVH (RR 0.63, 95% CI 0.42–0.96), NNB 22 (95% CI 12–193) ↓ Mortality (RR 0.63, 95% CI 0.47–0.84), NNB 20 (95% CI 12–58) | Moderate Moderate Moderate Low Low |
| Barkhuff et al., 2019 | Compared to ETT surfactant ± MV, LISA lead to: ↓ Death or BPD (RR 0.52, 95% CI 0.4–0.68), NNB 9 (95% CI 6–15) ↓ BPD (RR 0.57, 95% CI 0.44–0.75), NNB 14 (95% CI 9–28) ↓ Mortality (RR 0.60, 95% CI 0.44–0.82), NNB 19 (95% CI 11–52) ↓ MV within 72 h (RR 0.61, 95% CI 0.50–0.75), NNB 8 (95% CI 6–14) | – |
| Rigo et al., 2016 | Compared to ETT surfactant ± MV, LISA lead to: ↓ Early CPAP failure, (RR 0.67, 95% CI 0.53–0.84) ↓ MV requirements during NICU stay (RR 0.65, 95% CI 0.45–0.95) ↓ Death/BPD (RR 0.74, 95% CI 0.58–0.94), NNB 15 ↓ Need for MV within 72 h (RR 0.71, 95% CI 0.53–0.96) ↓ Death of BPD (RR 0.63, 95% CI 0.44–0.92) | – |
| Aldana-Aguirre et al., 2017 | Compared to ETT surfactant ±MV, LISA lead to: ↓ Death/BPD with LISA; RR = 0.75 (0.59–0.94) ↑ Surfactant reflux with LISA; RR = 2.52 (1.47–4.31) | – |
| Isayama, 2016 | Compared with MV, LISA group had: ↓ Death/BPD (OR 0.49, 95% CI 0.30–0.79) ↓ BPD (OR 0.53, 95% CI 0.27–0.96) ↓ Severe IVH (OR, 0.44, 95% CI 0.19–0.99) | Moderate Moderate Moderate Very low |

CI confidence interval, NNB number needed for treatment benefit, OR odds ratio, RR typical risk ratio.
Observational studies describing experience with LISA

A large body of observational evidence on LISA has been generated from Europe and Australia. In a study of 22–31 weeks GA infants born between 2009 and 2012 Göpel et al.91 compared the outcomes of infants receiving LISA (n = 1103) against matched control infants receiving selective surfactant therapy and MV (n = 1103). The LISA group had a decreased need for MV (41 vs 62%, p < 0.001), a lower BPD rate (12 vs 18%, p < 0.001), and a lower rate of death or BPD (14 vs 21%, p < 0.001). In a GNN study of 22–29 weeks GA infants born between 2009 and 2016 (n = 7533), Hartel et al.92 compared the outcomes of infants receiving no surfactant, LISA, and surfactant through ETT. The use of LISA increased during the study period (29% in 2009 to 50% in 2016). Infants treated with LISA (n = 2624) had a lower rate of mortality, BPD, severe IVH, PVL, PDA, and ROP compared to those treated with ETT surfactant (n = 3695). However, the subgroup of infants born at less than 26 weeks GA had a higher rate of spontaneous intestinal perforation (SIP) in the LISA group compared to the ETT surfactant group (10 vs 7.4%, p = 0.029). A multivariate analysis identified LISA as an independent risk factor for SIP (OR 1.42 (95% CI 1.06–1.89) among <26 weeks GA infants.

In a subsequent report, LISA had become the preferred method of surfactant administration within the GNN.93 Interestingly, this trend was also associated with an increase in the use of surfactant in ≤30 weeks GA infants across the network. Importantly, use of LISA was associated with decreased need for MV at every GA during the first 72 HOL, with a majority of infants ≥26 weeks GA completely escaping MV during their hospital stay. Among infants ≤25 weeks GA, although the need for MV in the first 72 HOL was lower, the need for MV during the overall hospital stay was high.93 Variables associated with CPAP failure among LISA-treated infants include lower birth weight and GA, frequent apnea, absence of maternal antenatal steroid therapy, and lower surfactant dose (<200 mg/kg).94

Our center introduced LISA as part of a quality improvement project (named OPTISURF) to minimize lung injury, which included optimization of CPAP and use of LISA in ≤29 weeks GA infants admitted to NICU on CPAP.95 The CPAP level was increased stepwise from 5 to 7 cm H2O if the FiO2 was ≥0.3, followed by LISA.96 Compared to historical controls, infants managed with the new algorithm (Fig. 1) received CPAP 7 cm H2O within 4 HOL more often, and had a lower rate of MV (within the first 72 HOL as well as during overall hospital stay), pneumothorax, and patent ductus arteriosus treatment. The lower need for MV within 72 HOL was seen in both infants 23–26 weeks GA, and 27 to 29 weeks GA. Of the LISA procedures, 39% required more than one attempt, and 55% were associated with desaturation and bradycardia. Most bradycardia and desaturation events were either self-resolving or required mild tactile stimulation, and/or supplemental oxygen.

IMPLEMENTING LISA

Based on the above evidence, many neonatal units in the US may choose to implement the practice of LISA, while others may choose to wait for more evidence to accumulate before adopting LISA. For units that wish to implement LISA, we provide the below guidance, based on our experience with implementing it in two large neonatal units. LISA should be used as part of a comprehensive strategy to optimize non-invasive support to maintain adequate FRC with interventions such as a bubble CPAP system, an optimum CPAP level, an optimal interface, airway clearance, positioning, and nursing care.100 CPAP failure rate varies between centers based on the proficiency of unit personnel with the use of non-invasive support, and all attempts should be made to ensure optimal CPAP delivery before

![Fig. 1 Algorithm for Management of Infants with RDS Using CPAP and Less Invasive Surfactant Administration. Optimization of CPAP and less invasive surfactant administration (OPTISURF) guideline.](image-url)
going down the path of LISA. Adequate time should be provided for CPAP to exert its beneficial effects before declaring CPAP failure.

Every unit implementing LISA should create a local clinical practice guideline based on evidence and consensus that includes stabilization of preterm infants after admission to NICU, optimization of non-invasive support, threshold and timing of LISA, administration of caffeine, eligibility and exclusion criteria for LISA, use of premedication (if any),2 non-pharmacological interventions to reduce pain and discomfort,2 the exact steps to be followed for the procedure, minimum competencies required for the personnel performing the procedure, and post-procedure management. All relevant unit personnel should be educated about the guideline, preferably using simulation,9,10 and readily available instructional videos.9 It is important to establish role clarity for individual team members of multidisciplinary teams during these simulation training sessions. The training of nurses and respiratory therapists is best conducted by discipline-specific team champions prior to practice change. An algorithm detailing criteria for escalation of CPAP and LISA should be kept at the bedside. The formulation of surfactant selected for use within the unit, and the standard surfactant dose and regimen should be used for LISA. The following material can be used and modified by individual units to create a local practice guideline.

**Selection of cases for LISA**

- Infants born ≤32 weeks gestation with respiratory distress requiring CPAP are eligible to receive LISA if they require FiO2 >0.3 after ensuring optimal CPAP therapy.
- Although a chest radiograph may help in confirming the diagnosis of RDS and excluding other causes of respiratory distress, i.e., pneumothorax, it should not delay the administration of surfactant in eligible infants.
- An arterial or capillary blood gas is recommended for infants requiring increasing oxygen requirement to identify severe respiratory acidosis.
- Contraindications for LISA:
  - Infants with rapidly worsening respiratory disease (e.g., persistently requiring FiO2 ≥0.70, PCO2 >70 mm Hg, pH <7.1) despite optimal non-invasive support.
  - Infants with frequent apnea (≥3 requiring stimulation in 1 h or any apnea requiring PPV) should be intubated and mechanically ventilated.

**LISA procedure steps and safety**

- LISA should be performed by clinicians proficient with intubation skills, who have undergone simulation-based training about LISA, and viewed the procedure video.
- A respiratory therapist should ensure optimum CPAP setup and level, infant positioning, and equipment before starting the LISA procedure. The CPAP level should be optimized to achieve and maintain optimal FRC during the procedure. Avoid discontinuation of CPAP during the procedure.
- Assemble the team including a nurse, respiratory therapist, a clinician proficient in intubation and LISA, and a supporting clinician.
- Gather supplies: 5 ml syringe, LISA catheter, sterile marker pen, sterile tape measure, sterile gloves, and drape. A LISA kit can be prepared that contains all these supplies. Also have an appropriate-sized face mask and a readily available functioning bag (or a T-piece resuscitator) for positive pressure ventilation.
- A nurse will draw up surfactant and 1 ml of air into a syringe.
- The first clinician will create a sterile field with drapes, wear sterile gloves, and will mark the insertion depth on the catheter with the pen (1 cm for ≤26 weeks GA, 1.5 cm for 27–28 weeks GA, 2 cm for ≥29 weeks GA).
- A nurse will monitor the vital signs during the procedure and an audible beat-to-beat monitor is activated for the procedure to alert the provider about bradycardia.
- The first clinician, using an appropriate size laryngoscope, will pass the catheter to the insertion depth, hold it in place at the lips, and withdraw the laryngoscope blade. Each attempt to place a thin catheter should last for a maximum of 30 s. The attempt should be abandoned if there is severe bradycardia or desaturation, or if ≥2 attempts are required. At that point, the infant should be intubated with an ETT.
- A second clinician will connect the syringe and instill surfactant in 4 aliquots over 1–2 min followed by 1 ml of air.
- The catheter is removed, and CPAP continued.
- An orogastric tube is placed and the stomach is aspirated to check for surfactant reflux.
- The nurse and RT will continuously monitor the infant during the procedure, and provide tactile stimulation and titration of FiO2 during the procedure. The infant should be continuously monitored as described above. The nurse should alert the clinicians about bradycardia.
- Persistent bradycardia or desaturation events may require face mask PPV during or after the procedure.
- Improvement in oxygenation will be seen within minutes after surfactant administration, confirming successful administration.
- Each procedure should be documented in a customized audit sheet (Supplementary File 1) that captures information about the number of attempts, duration of the procedure, duration and severity of desaturation and bradycardia during the procedure, other adverse events, surfactant reflux, and the interventions required to mitigate such events.

**Post-procedure monitoring after LISA**

- Infants developing respiratory failure on CPAP should be identified early by closely monitoring clinical status and blood gas values.
- The CPAP level should be titrated based on the need for supplemental oxygen and clinical status. Infants ≤26 weeks GA are at a higher risk of failing CPAP after LISA. Therefore, caution should be exercised while decreasing the CPAP level.
- Repeat doses of LISA should be considered at a FiO2 threshold of 0.30–0.4 at the standard time intervals. Repeat dose should also be considered if >50% of the dose of surfactant is aspirated from the stomach AND there is no significant improvement in the oxygenation (using either LISA or INSURE method).

**CONCLUSIONS**

The current body of evidence suggests that, in preterm infants who have worsening RDS after initial stabilization on nasal CPAP, use of LISA when compared to the INSURE or to continued MV has potential benefits, and might lead to a lower need for MV, decrease in BPD and composite death or BPD. The available long-term outcome studies show promise for improved neurodevelopmental outcomes with LISA. US-based clinicians are justified if, based on the available body of evidence they decide to routinely use LISA in preterm infants with RDS as an alternative to intubation and surfactant administration. A unit guideline based
on evidence and consensus for LISA should be developed that specifies all aspects of the procedure. In the absence of high-quality evidence, decisions about the exact catheter type and insertion method, and the use of pharmacologic and non-pharmacologic interventions to minimize pain and discomfort should be made based on the expertise and skill level at the individual center, and on clinician consensus. All team members involved in the LISA procedure should undergo extensive education and training in the technique of LISA and their specific roles. When LISA is implemented, details of every LISA procedure should be documented and individual outcomes followed. LISA should be part of an extensive strategy to promote non-invasive respiratory support in the NICU.

DATA AVAILABILITY
All data generated or analyzed during this study are included in this published article.

REFERENCES
1. Suresh, G. K. & Solli, R. F. Overview of surfactant replacement trials. J. Perinatol. 25, 540–544 (2005).
2. Sweet, D. G. et al. European Consensus Guidelines on the management of respiratory distress syndrome – 2019 update. Neonatology 115, 432–450 (2019).
3. Reynolds, P. et al. Less-invasive surfactant administration for neonatal respiratory distress syndrome: a consensus guideline. Neonatology 118, 586–592 (2019).
4. Ng, E. H. & Shah, V. Guidelines for surfactant replacement therapy in neonates. Paediatr. Child Health 26, 35–49 (2021).
5. Vento, M., Bohlin, K., Herting, E., Roehr, C. C. & Dargaville, P. A. Surfactant administration via thin catheter: a practical guide. Neonatology 116, 211–226 (2019).
6. Roberts, C. T. et al. Outcomes after introduction of minimally invasive surfactant therapy in two Australian tertiary neonatal units. J. Pediatr. 229, 141–146 (2021).
7. Verder, H. et al. Surfactant treatment of newborn infants with respiratory distress syndrome primarily treated with nasal continuous positive air pressure. A pilot study. Ugeskr Laeger. 154, 2136–2139 (1992).
8. Verder, H. et al. Surfactant therapy and nasal continuous positive air pressure for newborns with respiratory distress syndrome. Danish-Swedish Multicenter Study Group. N. Engl. J. Med. 331, 1051–1055 (1994).
9. Rojas-Reyes, M. X., Morley, C. J. & Solli, R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst. Rev. CD000510 (2012).
10. Schmolzer, G. M. et al. Non-invasive versus invasive respiratory support in preterm infants at birth: systematic review and meta-analysis. BMJ 347, f5980 (2013).
11. Subramaniam, P., Ho, J. J. & Davis, P. G. Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants. Cochrane Database Syst. Rev. CD001243 (2016).
12. Committee on Fetus and Newborn; American Academy of Pediatrics. Respiratory support in preterm infants at birth. Pediatrics. 133, 171–174 (2014).
13. LeVan, J. M. et al. Change in care among nonenrolled patients during and after a randomized trial. Pediatrics 132, e960–e970 (2013).
14. Weydig, H., Ali, N. & Kakkilaya, V. Noninvasive ventilation in the delivery room for the preterm infant. NeonReviews 20, e489–e499 (2019).
15. Kakkilaya, V. et al. Quality improvement project to decrease delivery room intubations in preterm infants. Pediatrics 143, e20180201 (2019).
16. Hatch, L. D. III et al. Changes in use of respiratory support for preterm infants in the US, 2008-2018. JAMA Pediatr. 175, 1017–1024 (2021).
17. Bell, E. F. et al. Mortality, in-hospital morbidity, care practices, and 2-year outcomes for extremely preterm infants in the US, 2013-2018. JAMA 327, 248–263 (2022).
18. Morley, C. J. et al. Nalip CPAP or intubation at birth for very preterm infants. N. Engl. J. Med. 358, 700–708 (2008).
19. Finer, N. N. et al. Early CPAP versus surfactant in extremely preterm infants. N. Engl. J. Med. 362, 1970–1979 (2010).
20. Sandhi, F. et al. Prophylactic or early selective surfactant combined with nCPAP in very preterm infants. Pediatrics 125, e1402–e1409 (2010).
21. Dunn, M. S., Kaempf, J. & Klerk, A. Randomized trial comparing 3 approaches to the initial respiratory management of preterm neonates. Pediatrics 128, e1069–e1076 (2011).
22. Ammari, A., Suri, M. & Milisavljevic, V. Variables associated with the early failure of nasal CPAP in very low birth weight infants. J. Pediatr. 147, 341–347 (2005).
23. Fuchs, H., Lindner, W., Leiprecht, A., Mendler, M. R. & Hummler, H. D. Predictors of early nasal CPAP failure and effects of various intubation criteria on the rate of mechanical ventilation in preterm infants of <29 weeks gestational age. Arch. Dis. Child Fetal Neonatal Ed. 96, F343–F347 (2011).
24. Dargaville, P. A., Ayyappan, A. & Paoli A. G. Continuous positive airway pressure failure in preterm infants: incidence, predictors and consequences. Neonatology 104, 8–14 (2013).
25. Dargaville, P. A. et al. Incidence and outcome of CPAP failure in preterm infants. Pediatrics 138, e20153985 (2016).
26. Kakkilaya, V. et al. Early predictors of continuous positive airway pressure failure in preterm neonates. J. Perinatol. 39, 1081–1088 (2019).
27. Kurepa, D., Perveen, S., Lipener, T. & Kakkilaya, V. The use of less invasive surfactant administration (LISA) in the United States with review of the literature. J. Perinatol. 39, 426–432 (2019).
28. Kribs, A. et al. Nonintubated surfactant application vs conventional therapy in extremely preterm infants: a randomized clinical trial. JAMA Pediatr. 169, 723–730 (2015).
29. Göpel, W. et al. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet 378, 1627–1634 (2011).
30. Kannaz, H. G., Erdeve, O., Canpolat, F. E., Mutlu, B. & Dilmen, U. Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. Pediatrics 131, e502–e509 (2013).
31. Dargaville, P. A. et al. Effect of minimally invasive surfactant therapy vs sham treatment on death or bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome: the OPTIMIST-a randomized clinical trial. JAMA 326, 2478–2487 (2021).
32. Kribs, A., Pillekamp, F., Hünseler, C., Vieziri, A. & Roth, B. Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants (postmenstrual age<27 weeks). Paediatr. Anaesth. 17, 364–369 (2007).
33. Dargaville, P. A. et al. Preliminary evaluation of a new technique of minimally invasive surfactant therapy. Arch. Dis. Child. Fetal Neonatal Ed. 96, F243–F248 (2011).
34. Rigo, V., Debauche, C., Maton, P., Broux, I. & Van Laere, D. Rigid catheters reduced duration of less invasive surfactant therapy procedures in manikins. Acta Paediatr. 106, 1091–1096 (2017).
35. Bhattacharya, S., Read, B., Miller, M. & da Silva, O. Impact of catheter choice on procedural success of minimally invasive surfactant therapy. Am. J. Perinatol. 2021. https://doi.org/10.1055/s-0041-1733955 [Epub ahead of print].
36. NCT. A Study in Preterm Neonates With RDS to Compare CUROSURF® Administration Through USA and Conventional Administration USPAP. https://clinicaltrials.gov/show/NCT02772081 (2016).
37. Maiwald, C. A. et al. Clinical evaluation of an application aid for less-invasive surfactant administration (LISA). Arch. Dis. Child Fetal Neonatal Ed. 106, 211–214 (2021).
38. Marshall, T. A., Deeder, R., Pai, S., Berkowitz, G. P. & Austin, T. L. Physiologic changes associated with endotracheal intubation in preterm infants. Crit. Care Med. 12, 501–503 (1984).
39. Stow, P. J., McLeod, M. E., Burrows, F. A. & Creighton, R. E. Anterior fontanelle pressure responses to tracheal intubation in the awake and anaesthetized infant. Br. J. Anaesth. 60, 167–170 (1988).
40. Friesen, R. H., Honda, A. T. & Thiemke, R. E. Changes in anterior fontanelle pressure in preterm neonates during tracheal intubation. Anesth. Analg. 66, 874–878 (1987).
41. Raju, T. N., Vidyasagar, D., Torres, C., Conti, G. & De Luca, D. Continuous positive airway pressure delivery during less invasive surfactant administration: a physiologic study. J. Perinatol. 38, 271–277 (2018).
42. De Luca, D. et al. Less invasive surfactant administration: a word of caution. Lancet Child Adolesc. health 4, 331–340 (2020).
43. Peterson, J., den Boer, M. C. & Roehr, C. C. To sedate or not to sedate for less invasive surfactant administration: an ethical approach. Neonatology 118, 639–646 (2021).
61. Gupta, B. K., Saha, A. K., Mukherjee, S. & Saha, B. Minimally invasive surfactant administration for the treatment of respiratory distress syndrome: feasibility and outcome. J. Perinatol. 24, 88–93 (2004).

62. Han, T. et al. Minimally invasive surfactant administration for the treatment of respiratory distress syndrome-an updated meta-analysis. Arch. Dis. Child. Fetal Neonatal Ed. 106, 474–487 (2021).

63. Abdel-Latif, M. E., Davis, P. G., Wheeler, K. L., De Paoli, A. G. & Dargaville, P. A. Minimally invasive surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database Syst. Rev. 5, Cd011672 (2021).

64. Ten Centre Study, G. Ten centre trial of artificial lung surfactant (artificial lung expanding compound) in very premature babies. Br. Med. J. (Clin. Res. Ed.) 294, 991–996 (1987).

65. Murphy, M. C. et al. Study protocol for the POPART study-prophylactic oropharyngeal surfactant for preterm infants: a randomised trial. BMJ Open 10, e035994 (2020).

66. Jorch, G. et al. Surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants. Pediatr. Pulmonol. 24, 222–224 (1997).

67. Cummins, J. J. et al. Aerosolized calf surfactant for newborns with respiratory distress syndrome: a randomized trial. Pediatrics 146, e2019367 (2020).

68. Brimacombe, J. et al. The laryngeal mask airway for administration of surfactant in two neonates with respiratory distress syndrome. Paediatr. Anaesth. 14, 188–190 (2004).

69. Pinheiro, J. M., Santana-Rivas, Q. & Pezzano, C. Randomized trial of laryngeal mask airway versus endotracheal intubation for surfactant delivery. J. Perinatol. 36, 196–201 (2016).

70. Roberts, K. D. et al. Laryngeal mask airway for surfactant administration in neonates: a randomized, controlled trial. J. Pediatr. 193, 40–46.e14 (2018).

71. ANZCTR. Surfactant Administration by Supraglottic Airway for Preterm Infants with Respiratory Distress Syndrome: The SURFSUP 1 Trial. https://trialsearch.who.int/TrialID=ACTRN12620011849655 (2020).

72. Hering, E. et al. Two-year outcome data suggest that less invasive surfactant administration (LISA) is safe. Results from the follow-up of the randomised controlled AMV (avoid mechanical ventilation) study. Eur. J. Pediatr. 179, 1309–1313 (2020).

73. Mehler, K. et al. Outcome of extremely low gestational age newborns after introduction of a revised protocol to assist preterm infants in their transition to extrauterine life. Acta Paediatr. 108, 1322–1329 (2019).

74. Dekker, J. et al. Sedation during minimal invasive surfactant therapy in very premature babies: a network meta-analysis. Acta Paediatr. 109, 592–599 (2020).

75. Bourgoin, L. et al. Administering atropine and ketamine before less invasive surfactant administration: a network meta-analysis. Acta Paediatr. 109, 1015–1022 (2020).

76. Cummings, J. J. et al. Aerosolized calfactant for newborns with respiratory distress syndrome: a randomized trial. Pediatrics 146, e2019367 (2020).

77. Descamps, C. S. et al. Propofol for sedation during less invasive surfactant administration in preterm infants: a systematic review and meta-analysis. J. Trop. Pediatr. 65, 3053–3058 (2021).

78. Gulczyńska, E., Szczapa, T., Hojżewski, R., Borszewsko-Kornacka, M. & Rutkowska, M. Fraction of inspired oxygen as a predictor of CPAP failure in preterm infants with respiratory distress syndrome: a prospective multicenter study. Neonatology 116, 171–178 (2019).

79. Papazanian, V. B. et al. Decreasing continuous positive airway pressure failure in preterm infants. Pediatrics 148, e2020014191 (2021).

80. Göpel, W. et al. Less invasive surfactant administration is associated with improved pulmonary outcomes in spontaneously breathing preterm infants. Acta Paediatr. 104, 241–246 (2015).

81. Hartel, C. et al. Less invasive surfactant administration and complications of preterm birth. Sci. Rep. 8, 8333 (2018).

82. Herting, E., Hartel, C. & Göpel, W. Less invasive surfactant administration (LISA): chances and limitations. Arch. Dis. Child. Fetal Neonatal Ed. 104, F655–F659 (2019).

83. Langhammer, K. et al. Treatment and outcome data of very low birth weight infants treated with less invasive surfactant administration in comparison to intubation and mechanical ventilation in the clinical setting of a cross-sectional observational multicenter study. Eur. J. Pediatr. 177, 1207–1217 (2018).

84. Janssen, L. C. et al. Minimally invasive surfactant therapy failure risk factors and outcome. Arch. Dis. Child. Fetal Neonatal Ed. 104, F636–F642 (2019).

85. Wung, J. T., Driscoll, J. M. Jr., Epstein, R. A. & Hyman, A. L. A new device for CPAP by nasal route. Crit. Care Med. 3, 76–78 (1975).

86. Morley, C. Continuous distending pressure. Arch. Dis. Child. Fetal Neonatal Ed. 81, F152–F156 (1999).
98. De Paoli, A. G., Davis, P. G., Faber, B. & Morley, C. J. Devices and pressure sources for administration of nasal continuous positive airway pressure (NCPAP) in preterm neonates. *Cochrane Database Syst. Rev.* **2008**, Cd002977 (2008).

99. Jasani, B., Ismail, A., Rao, S. & Patole, S. Effectiveness and safety of nasal mask versus binasal prongs for providing continuous positive airway pressure in preterm infants—a systematic review and meta-analysis. *Pediatr. Pulmonol.* **53**, 987–992 (2018).

100. Bonner, K. M. & Mainous, R. O. The nursing care of the infant receiving bubble CPAP therapy. *Adv. Neonatal Care* **8**, 78–95 (2008).

101. Aly, H. & Mohamed, M. A. An experience with a bubble CPAP bundle: is chronic lung disease preventable? *Pediatr. Res.* **88**, 444–450 (2020).

102. Sawyer, T. et al. Learn, see, practice, prove, do, maintain: an evidence-based pedagogical framework for procedural skill training in medicine. *Academic Med.* **90**, 1025–1033 (2015).

**ACKNOWLEDGEMENT**

Dr. Kakkilaya acknowledges the support from Parkland Community Health Plan.

**AUTHOR CONTRIBUTIONS**

V.K. conceptualized and designed the study, analyzed and interpreted the data, drafted the initial manuscript, and reviewed and revised the manuscript. K.S.G. conceptualized and designed the study, analyzed and interpreted the data, provided the original structure and organization of the manuscript, and reviewed and revised the manuscript. ACKNOWLEDGEMENT: Dr. Kakkilaya acknowledges the support from Parkland Community Health Plan.

**COMPETING INTERESTS**

The authors declare no competing interests.

**ADDITIONAL INFORMATION**

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41390-022-02265-8.

Correspondence and requests for materials should be addressed to Venkatakrishna Kakkilaya.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.